[{"id":"65f11ba4-54ff-43fd-a6f2-54316429b85b","acronym":"ECOG-ACRIN E1912","url":"https://clinicaltrials.gov/study/NCT02048813","created_at":"2021-01-17T17:35:11.745Z","updated_at":"2024-07-02T16:34:37.153Z","phase":"Phase 3","brief_title":"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT02048813 - ECOG-ACRIN E1912","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CCND1 • IGH • CD4 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CD4 positive","tags":["CD20 • CCND1 • IGH • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • cyclophosphamide • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 529","initiation":"Initiation: 02/20/2014","start_date":" 02/20/2014","primary_txt":" Primary completion: 10/24/2018","primary_completion_date":" 10/24/2018","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-07"},{"id":"098e0ee6-b95b-451c-a612-ce0d682ed1c8","acronym":"CheckMate-038","url":"https://clinicaltrials.gov/study/NCT01621490","created_at":"2021-01-18T06:57:16.141Z","updated_at":"2024-07-02T16:35:07.959Z","phase":"Phase 1","brief_title":"PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma","source_id_and_acronym":"NCT01621490 - CheckMate-038","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" CD8 • IFNG • CXCL10 • CXCL9 • CD4","pipe":" | ","alterations":" CD8 positive • CD4 positive","tags":["CD8 • IFNG • CXCL10 • CXCL9 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive • CD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 09/27/2012","start_date":" 09/27/2012","primary_txt":" Primary completion: 09/12/2017","primary_completion_date":" 09/12/2017","study_txt":" Completion: 10/25/2018","study_completion_date":" 10/25/2018","last_update_posted":"2024-04-23"},{"id":"6995371f-14d0-437d-91fa-8e1b8845e670","acronym":"","url":"https://clinicaltrials.gov/study/NCT02326805","created_at":"2021-01-18T11:02:21.838Z","updated_at":"2024-07-02T16:35:42.583Z","phase":"Phase 2","brief_title":"PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance","source_id_and_acronym":"NCT02326805","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression • CD4 positive","tags":["PD-L1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ProstVac (rilimogene galvacirepvec)"],"overall_status":"Completed","enrollment":" Enrollment 154","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 11/30/2018","primary_completion_date":" 11/30/2018","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2023-07-19"},{"id":"a494ab91-02f5-4029-9cc0-0d8baf140054","acronym":"","url":"https://clinicaltrials.gov/study/NCT00456807","created_at":"2021-01-29T06:57:03.989Z","updated_at":"2024-07-02T16:37:27.005Z","phase":"Phase 3","brief_title":"Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged \u003e/= 26 Years","source_id_and_acronym":"NCT00456807","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" CD4 positive","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cervarix (recombinant human papillomavirus bivalent vaccine)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 01/01/2008","primary_completion_date":" 01/01/2008","study_txt":" Completion: 01/01/2008","study_completion_date":" 01/01/2008","last_update_posted":"2016-12-16"}]